N/A N=84 Evaluation of a Computer-Based, Self-Management Tool for People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Between Group Differences in Diabetes Knowledge — 67; 64 Percent of items correct
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
Coronary Artery Disease
Primary: Platelet Reactivity Measured by VerifyNow — 16.9; 12.6 P2Y12 reaction units
Phase 3 N=45 A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Central Precocious Puberty (CPP)
Primary: Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24…
Phase 1 N=20 Study of Testosterone and rHGH in FSHD
Facioscapulohumeral Muscular Dystrophy
Primary: Number of Participants Who Experienced an AE — 14 Participants
Phase 2 N=42 Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Neovascular Age-related Macular Degeneration · Wet Age-related Macular Degeneration
Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) — 6; 6; 6; 12 Participants
N/A N=31 Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!
Osteoporosis · Obesity · Weight Loss
Primary: Bone Mineral Density-Total Body — -0.3; -1.1 percent change in BMD (g/cm2) — p=<0.05
Phase 3 N=1,255 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants
Phase 3 N=472 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
N/A N=61 Endothelial Dysfunction in Obese Children
Obesity · Atherosclerosis
Primary: Change From Baseline in Reactive Hyperemia Index at 5 and 10 Months — 1.9; 1.5; 2.01; 1.55 arbitrary units — p=<0.05
Phase 1 N=16 Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
Chronic Kidney Disease
Primary: Maximum Plasma Concentration (Cmax) of Apraglutide — 39.5; 65.8 ng/mL
Phase 2 N=2 BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage III Pancreatic Cancer
Primary: Median Overall Survival (OS) — 0.934 years
N/A N=255 Promoting The Self-Regulation Of Energy Intake
Obesity
Primary: Children's BMI Percentiles — 49; 41; 15; 18 Participants — p=<0.05
N/A N=78 Project SMART Automated Pillbox Study
HIV/AIDS · Cocaine Use
Primary: Adherence to Anti-Retroviral Therapy (ART) at the End of 12-Week Intervention Period — 91.07; 96.00; 99.82; 94.81 percentage of times pills taken
Phase 4 N=114 A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
Asthma
Primary: Percentage of Participants Making at Least One Critical Error After Reading the Patient Information Leaflets (PIL) — 6; 26 Percentage of participants — p=<0.001
Phase 3 N=3,298 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Healthy Participants
Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…